BioCryst price target raised to $24 from $21 at H.C. Wainwright H.C. Wainwright raised its price target for BioCryst shares to $24 saying two overhangs have been removed with the positive Phase 2a data for oral kallikrein inhibitor 4161 and the recent equity financing. The firm reiterates a Buy rating on the stock.
BioCryst upgraded to Buy on BCX7353 potential at BofA/Merrill As previously reported, BofA/Merrill upgraded BioCryst to Buy from Neutral and increased its price target to $19 from $12. The firm raised the probability of BCX7353 approval to 40% from 25% given validation of the plasma kallikrein target by both ‘4161 and competitor product and now assign a $13/share value versus near zero previously. BofA/Merrill is now assigning a modest negative value for '4161 versus approximately $7/share previously.